3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma, T-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Paclitaxel
79
Carboplatin
66
pembrolizumab
61
Bevacizumab
56
Cisplatin
48
Specimen Handling
29
Drug Therapy
26
Blood Specimen Collection
24
Cyclophosphamide
20
olaparib
19
Taxes
17
Magnetic Resonance Spectroscopy
16
Letrozole
16
Gemcitabine
16
Biopsy
16
liposomal doxorubicin
15
niraparib
14
fludarabine
14
Brachytherapy
14
Radiotherapy
13
abemaciclib
12
Topotecan
11
Nivolumab
11
Injections
11
Doxorubicin
11
lenvatinib
10
Fluorouracil
10
atezolizumab
9
Surveys and Questionnaires
9
Standard of Care
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Solutions
×
Gynecologic
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled